Aspirin, Ibuprofen, and the Risk for Colorectal Cancer in Lynch Syndrome

Journal of the National Cancer Institute

Volumn 107, Issue 9, 2015, Pages

  Ouakrim, Driss Ait ^a   Dashti, Seyedeh Ghazaleh ^a   Chau, Rowena ^a   Buchanan, Daniel D ^a,b   Clendenning, Mark ^b   Rosty, Christophe ^b,c   Winship, Ingrid M ^b,d   Young, Joanne P ^e,f,g   Giles, Graham G ^a,h   Leggett, Barbara ⁱ   Macrae, Finlay A ^b,d   Ahnen, Dennis J ^j   Casey, Graham ^k   Gallinger, Steven ^l   Haile, Robert W ^m   Le Marchand, Loïc ⁿ   Thibodeau, Stephen N ^o   Lindor, Noralane M ^p   Newcomb, Polly A ^q,r   Potter, John D ^q,r,s   Baron, John A ^t   Hopper, John L ^a,u   Jenkins, Mark A ^a   Win, Aung Ko ^a   more..

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

^e QUEEN ELIZABETH HOSPITAL   (Australia)

^f SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^g UNIVERSITY OF ADELAIDE   (Australia)

^h CANCER EPIDEMIOLOGY CENTRE   (Australia)

ⁱ QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^j UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^l MOUNT SINAI HOSPITAL   (Canada)

^m STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^o MAYO CLINIC   (United States)

^p MAYO CLINIC   (United States)

^q Fred Hutchinson Cancer Research Center   (United States)

^r UNIVERSITY OF WASHINGTON   (United States)

^s MASSEY UNIVERSITY   (New Zealand)

^t UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^u Seoul National University   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; IBUPROFEN; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6;

ADULT; AGED; ARTICLE; CANCER RISK; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GERMLINE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 84942022355     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv170     Document Type: Article

References (60)

1. Lynch HT, Lynch PM, Lanspa SJ, et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal rami-fcations. Clin Genet. 2009;76(1):1-18.
2. Dunlop MG, Farrington SM, Nicholl I, et al. Population carrier frequency of hMSH2 and hMLH1 mutations. Br J Cancer. 2000;83(12):1643-1645.
3. Hampel H, de la Chapelle A. The search for unaffected individuals with Lynch syndrome: do the ends justify the means? Cancer Prev Res (Phila). 2011;4(1):1-5.
4. Aaltonen LA, Sankila R, Mecklin JP, et al. A novel approach to estimate the proportion of hereditary nonpolyposis colorectal cancer of total colorectal cancer burden. Cancer Detect Prev. 1994;18(1):57-63.
5. Hopper JL. Application of genetics to the prevention of colorectal cancer. Recent results in cancer research 2005;Fortschritte der Krebsforschung. Pro-gres dans les recherches sur le cancer. 166:17-33.
6. Dowty JG, Win AK, Buchanan DD, et al. Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat. 2013;34(3):490-497.
7. Jarvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118(5):829-834.
8. Cairns SR, Scholefeld JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010;59(5):666-689.
9. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008;58(3):130-160.
10. NHMRC. Clinical practice guidelines for the prevention, early detection and management of colorectal cancer. The Australian Cancer Network website. http://www.cancer.org.au/guidelines or http://www.nhmrc.gov.au/publica-tions/synopses/cp106/cp106syn.htm.
11. Vasen HF, Blanco I, Aktan-Collan K, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut. 2013;62(6):812-823.
12. Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: A systematic review. JAMA. 2006;296(12):1507-1517.
13. Chan AT, Giovannucci EL, Meyerhardt JA, et al. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology. 2008;134(1):21-28.
14. Cuzick J, Otto F, Baron JA, et al. Aspirin and non-steroidal anti-infammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009;10(5):501-507.
15. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369(9573):1603-1613.
16. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colo-rectal cancer incidence and mortality: 20-year follow-up of fve randomised trials. Lancet. 2010;376(9754):1741-1750.
17. Cole BF, Logan RF, Halabi S, et al. Aspirin for the chemoprevention of colo-rectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst. 2009;101(4):256-266.
18. Ishikawa H, Mutoh M, Suzuki S, et al. The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial. Gut. 2014;63(11):1755-1759.
19. Burn J, Bishop DT, Mecklin JP, et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med. 2008;359(24):2567-2578.
20. Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378(9809):2081-2087.
21. Newcomb PA, Baron J, Cotterchio M, et al. Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(11):2331-2343.
22. Rumilla K, Schowalter K V, Lindor NM, et al. Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated Lynch syndrome cases. J Mol Diagn. 2011;13(1):93-99.
23. Southey MC, Jenkins MA, Mead L, et al. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. J Clin Oncol. 2005;23(27):6524-6532.
24. Senter L, Clendenning M, Sotamaa K, et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology. 2008;135(2):419-428.
25. Win AK, Young JP, Lindor NM, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol. 2012;30(9):958-964.
26. Antoniou AC, Goldgar DE, Andrieu N, et al. A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. Genet Epidemiol. 2005;29(1):1-11.
27. Andrieu N, Easton D F, Chang-Claude J, et al. Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group. J Clin Oncol. 2006;24(21):3361-3366.
28. Antoniou AC, Spurdle AB, Sinilnikova OM, et al. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet. 2008;82(4):937-948.
29. Win AK, Dowty JG, Antill YC, et al. Body mass index in early adulthood and endometrial cancer risk for mismatch repair gene mutation carriers. Obstet Gynecol. 2011;117(4):899-905.
30. Pande M, Lynch PM, Hopper JL, et al. Smoking and Colorectal Cancer in Lynch Syndrome: Results from the Colon Cancer Family Registry and The University of Texas M.D. Anderson Cancer Center. Clin Cancer Res. 2010;16(4):1331-1339.
31. American Cancer Society. Cancer Facts & Figures 2013. In. Atlanta: American Cancer Society; 2013.
32. Jenkins MA, Baglietto L, Dowty JG, et al. Cancer Risks For Mismatch Repair Gene Mutation Carriers: A Population-Based Early Onset Case-Family Study. Clin Gastroenterol Hepatol. 2006;4(4):489-498.
33. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81(3):515-526.
34. Hosmer D, Lemeshow S, May S. Applied Survival Analysis. Regression Modeling of Time to Event Data. New York, NY: John Wiley & Sons; 1999.
35. Rogers W. Regression standard errors in clustered samples. Stata Technical Bulletin. 1999;3:19-23.
36. Williams RL. A note on robust variance estimation for cluster-correlated data. Biometrics. 2000;56(2):645-646.
37. Rebbeck TR, Mitra N, Domchek SM, et al. Modifcation of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. Cancer Res. 2011;71(17):5792-5805.
38. Ye X, Fu J, Yang Y, et al. Dose-risk and duration-risk relationships between aspirin and colorectal cancer: a meta-analysis of published cohort studies. PLoS One. 2013;8(2):e57578.
39. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326(7382):219.
40. Burn J, Bishop DT, Chapman PD, et al. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila). 2011;4(5):655-665.
41. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993;328(18):1313-1316.
42. Hallak A, Alon-Baron L, Shamir R, et al. Rofecoxib reduces polyp recurrence in familial polyposis. Dig Dis Sci. 2003;48(10):1998-2002.
43. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cycloox-ygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342(26):1946-1952.
44. Winde G, Schmid KW, Schlegel W, et al. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Advantages of a low-dose nonsteroidal anti-infammatory drug regimen in reversing adenomas exceeding 33 months. Dis Colon Rectum. 1995;38(8):813-830.
45. Reeves MJ, Newcomb PA, Trentham-Dietz A, et al. Nonsteroidal anti-infam-matory drug use and protection against colorectal cancer in women. Cancer Epidemiol Biomarkers Prev. 1996;5(12):955-960.
46. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res. 1988;48(15):4399-4404.
47. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-infammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94(4):252-266.
48. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007;356(21):2131-2142.
49. He TC, Chan TA, Vogelstein B, et al. PPARdelta is an APC-regulated target of nonsteroidal anti-infammatory drugs. Cell. 1999;99(3):335-345.
50. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83(3):493-501.
51. Chan TA, Morin PJ, Vogelstein B, et al. Mechanisms underlying nonsteroi-dal antiinfammatory drug-mediated apoptosis. Proc Natl Acad Sci USA. 1998;95(2):681-686.
52. Marx J. Cancer research. Anti-infammatories inhibit cancer growth-but how? Science. 2001;291(5504):581-582.
53. Greenspan EJ, Madigan JP, Boardman LA, et al. Ibuprofen inhibits activation of nuclear {beta}-catenin in human colon adenomas and induces the phosphorylation of GSK-3{beta}. Cancer Prev Res (Phila). 2011;4(1):161-171.
54. Jankowski J, Barr H, Moayyedi P. Does aspirin really reduce the risk of colon cancer? Lancet. 2012;379(9826):1586-1587; author reply 1587.
55. Jankowski J, Barr H, Wang K, et al. Diagnosis and management of Barrett's oesophagus. BMJ. 2010;341:c4551.
56. Bjarnason I, Price AB, Zanelli G, et al. Clinicopathological features of non-steroidal antiinfammatory drug-induced small intestinal strictures. Gastro-enterology. 1988;94(4):1070-1074.
57. Ishihara M, Ohmiya N, Nakamura M, et al. Risk factors of symptomatic NSAID-induced small intestinal injury and diaphragm disease. Aliment Pharmacol Ther. 2014;40(5):538-547.
58. Kaufman DW, Kelly JP, Wiholm BE, et al. The risk of acute major upper gastrointestinal bleeding among users of aspirin and ibuprofen at various levels of alcohol consumption. Am J Gastroenterol. 1999;94(11):3189-3196.
59. Cuzick J, Thorat MA, Bosetti C, et al. Estimates of benefts and harms of prophylactic use of aspirin in the general population. Ann Oncol. 2014;26(1):47-57.
60. van Kruijsdijk RC, Visseren FL, Ridker PM, et al. Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women. Heart. 2014;101(5):369-376.